AstraZeneca says its Faslodex shows superiority in comparison study for advanced breast cancer

pharmafile | May 27, 2016 | News story | Medical Communications, Research and Development, Sales and Marketing |  AstraZeneca, breast cancer, comparision study, drug trial 

UK drugmaker AstraZeneca (LSE: AZN) on Friday said late-stage comparison trials for its drug to treat advanced breast cancer showed superiority over other treatment.

The company said the study compared its Faslodex (fulvestrant) against Arimidex (anastrozole) for breast cancer, in post-menopausal women.

Sean Bohen, chief medical officer at AstraZeneca, said: “The Falcon results bring us closer to offering more and earlier treatment options to postmenopausal women with HR+ locally-advanced or metastatic breast cancer; the potential to delay disease progression is important for these patients as there is currently no cure. Faslodex has over 10 years of clinical evidence and we are committed to exploring its potential along with the rest of our outstanding oncology portfolio.”

A full evaluation of the data is ongoing and the results are expected to be presented at a medical meeting in 2016, the company said in a statement.

Faslodex is approved as a treatment for postmenopausal women with breast cancer whose cancer has progressed following anti-oestrogen therapy.

In March, the US Food and Drug Administration approved Faslodex, in combination with palbociclib, to treat advanced or metastatic breast cancer.

The most advanced stage of breast cancer (stage IV) occurs when cancer cells have spread beyond the initial tumour site to other parts of the body outside of the breast. Since there is no cure for ABC, the goal of current treatment is to delay disease progression.

Anjali Shukla